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Phosphotyrosine profiling of human 
cerebrospinal fluid
Gajanan Sathe1,2,7, Chan Hyun Na3,4,6, Santosh Renuse2,3, Anil Madugundu1,2,7, Marilyn Albert4, 
Abhay Moghekar4* and Akhilesh Pandey1,3,5* 
Abstract 
Background: Cerebrospinal fluid (CSF) is an important source of potential biomarkers that affect the brain. Biomark-
ers for neurodegenerative disorders are needed to assist in diagnosis, monitoring disease progression and evaluating 
efficacy of therapies. Recent studies have demonstrated the involvement of tyrosine kinases in neuronal cell death. 
Thus, neurodegeneration in the brain is related to altered tyrosine phosphorylation of proteins in the brain and iden-
tification of abnormally phosphorylated tyrosine peptides in CSF has the potential to ascertain candidate biomarkers 
for neurodegenerative disorders.
Methods: In this study, we used an antibody-based tyrosine phosphopeptide enrichment method coupled with 
high resolution Orbitrap Fusion Tribrid Lumos Fourier transform mass spectrometer to catalog tyrosine phosphoryl-
ated peptides from cerebrospinal fluid. The subset of identified tyrosine phosphorylated peptides was also validated 
using parallel reaction monitoring (PRM)-based targeted approach.
Results: To date, there are no published studies on global profiling of phosphotyrosine modifications of CSF proteins. 
We carried out phosphotyrosine profiling of CSF using an anti-phosphotyrosine antibody-based enrichment and 
analysis using high resolution Orbitrap Fusion Lumos mass spectrometer. We identified 111 phosphotyrosine pep-
tides mapping to 66 proteins, which included 24 proteins which have not been identified in CSF previously. We then 
validated a set of 5 tyrosine phosphorylated peptides in an independent set of CSF samples from cognitively normal 
subjects, using a PRM-based targeted approach.
Conclusions: The findings from this deep phosphotyrosine profiling of CSF samples have the potential to identify 
novel disease-related phosphotyrosine-containing peptides in CSF.
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Background
Cerebrospinal fluid (CSF) is a colorless, clear liquid that 
surrounds the brain and spinal cord [1] and conven-
tionally acts as a shock absorber in the central nervous 
system by maintaining electrolytes as well as acid–base 
balance [2]. It also plays a crucial role in neurodevelop-
ment and waste clearance in addition. CSF is produced 
from arterial blood by the choroid plexuses of the lateral 
and fourth ventricles. It also secretes nutrients, filters 
metabolites from the blood and eliminates waste prod-
ucts from the brain [3]. CSF regulates neuronal activity 
through neuropeptides and hormones [4]. As a proximal 
fluid, CSF reflects the health/disease state of the nerv-
ous system and is likely to have a higher concentration of 
protein biomarkers, which provide a direct readout of the 
state of the central nervous system [5]. Investigating the 
proteomic profile of this fluid can be beneficial in diag-
nosing various neurological disorders including Alzhei-
mer’s, Parkinson’s diseases and multiple sclerosis.
Phosphorylation is one of the most commonly stud-
ied post-translational modifications (PTMs), and 
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phosphorylation of proteins at specific sites are already 
used as biomarkers in neurological disorders (e.g.: phos-
phorylated tau in AD) [6–8]. Additionally, phospho-
rylation plays important roles in cell communication, 
signaling, aging, and cell adhesion [9, 10]. For example, 
phosphorylation of tyrosine residues by tyrosine kinases 
such as c-Abl has been reported to have a central role 
in neurodegeneration [11]. The biofluid phosphopro-
teome contains phosphorylated proteins either secreted 
from cells or leak from the intracellular content of dam-
aged cells. Recent studies have shown that proteins may 
undergo phosphorylation in the extracellular compart-
ment through the action of extracellular kinases [12, 13]. 
The discovery of novel secreted kinase VLK and Casein 
kinase, which are responsible for the phosphorylation 
of the major class of secreted proteins, has led to an 
increased interest in secreted phosphoproteins and their 
roles [14, 15]. Unfortunately, there are limited studies on 
direct analysis of phosphorylation in biofluids such as 
plasma phosphoproteins [16], CSF [17] and saliva [18]. 
Although several studies have been carried out on the 
proteomic profiling of CSF, limited studies were focused 
on its phosproteome [19–21]. Earlier targeted studies on 
neurological disorders focused on phosphorylation alter-
ation on serine and threonine sites, including an increase 
in tau, synuclein phosphorylation in neurological disor-
ders [22, 23]. Heegaard et al. in a previous study carried 
out phosphoproteomic profiling of cerebrospinal fluid 
using  TiO2 based enrichment. They identified 56 novel 
phosphorylation sites on 38 proteins [19]. In another 
study Nakamura et  al. used titanium based and IMAC 
enrichment followed by use of EDTA for phosphopep-
tides analysis leading to identification of 123 phospho-
peptides [20]. Molecularly imprinted polymers that 
have binding affinity sites for pS or pY were also used for 
enrichment of phosphopeptides from CSF. This lead to 
identification of 47 phosphopeptides corresponding to 24 
proteins [21]. All earlier mass spectrometry studies were 
focused on global phosphorylation of CSF.
Stoichiometrically, tyrosine phosphorylation is less 
abundant, and its detection is more difficult in global 
profiling although it plays an important role in regula-
tion of neuronal maturation and synaptic plasticity [24]. 
Tyrosine phosphopeptides can be enriched using an 
antibody-based immunoprecipitation approach [25]. In 
an earlier study by Yuan X et al., phosphotyrosyl-proteins 
in CSF were detected using 2D gel electrophoresis. They 
identified four tyrosine phosphorylated proteins includ-
ing kallikrein-6 precursor, complement C4 gamma-chain, 
gelsolin, and ceruloplasmin precursor. The major limita-
tion of this approach was that the technology used was 
less sensitive and low throughput [26]. In this study, we 
carried out phosphotyrosine profiling to investigate the 
tyrosine phosphorylation of proteins that are detectable 
in the CSF. Phosphotyrosine-containing peptides were 
enriched by an anti-phosphotyrosine antibody-based 




Anti-phosphotyrosine rabbit monoclonal antibody 
(P-Tyr-1000) beads were obtained from Cell Signaling 
Technology (Danvers, MA). TPCK-treated trypsin was 
obtained from Worthington Biochemical Corp. (Lake-
wood, NJ). All other reagents used in this study were 
from Fisher Scientific (Pittsburgh, PA).
Lumbar CSF samples
The sample group consisted of subjects with normal 
pressure hydrocephalus (NPH) and cognitively normal 
individuals seen as part of the BIOCARD study [27]. The 
participants underwent a lumbar puncture in the fasted 
state in the morning and the CSF was collected in poly-
propylene vials and stored at − 80  °C. NPH CSF was 
collected via an indwelling lumbar catheter and in cog-
nitively normal individuals by lumbar puncture. We have 
collected CSF samples from 3 NPH and 8 cognitively 
normal individuals. All individuals selected for inclusion 
within the study provided informed consented prior to 
sample collection.
Protein concentration and in‑solution trypsin digestion 
of proteins from CSF
CSF samples were adjusted to 20  mM HEPES, 1  mM 
sodium orthovanadate, 2.5  mM sodium pyrophosphate, 
1  mM β-glycerophosphate. CSF was concentrated 10 
times by volume using 3 kDa cutoff spin columns (Micro-
con Ultracel YM-3, Millipore). The concentration of pro-
tein from these samples was measured using the BCA 
protein estimation method. We used protein from 100 ml 
CSF from all three samples for the in-solution digestion 
and the amount of the proteins present in the samples was 
respectively 49, 51 and 52 mg. For reduction, dithiothrei-
tol (Sigma) was added to a final concentration of 10 mM 
and the mixture was incubated at 56  °C for 45 min. For 
alkylation, the mixture was cooled to room temperature 
and iodoacetamide was added to a final concentration of 
20 mM and incubated at room temperature for 45 min in 
the dark. CSF samples were subjected to digestion with 
TPCK treated trypsin with 1:50 trypsin to CSF protein 
ratio (Worthington Biochemical Corp, Lakewood, NJ) 
for 12–16  h at room temperature. Protein digests were 
acidified by 1% trifluoroacetic acid (TFA), centrifuged 
at 12,000×g for 5  min and supernatant desalted using 
Page 3 of 11Sathe et al. Clin Proteom  (2018) 15:29 
 C18 Sep-Pak cartridge (Waters, Cat#WAT051910) and 
lyophilized.
Immunoaffinity purification of tyrosine phosphopeptides
The lyophilized peptide mixtures were dissolved in in 
IAP buffer containing 50  mM MOPS pH 7.2, 10  mM 
sodium phosphate and 50 mM NaCl. Prior to phosphoty-
rosine enrichment, the P-Tyr-1000 beads (Cell Signaling 
Technology, Danvers, MA) were washed twice with IAP 
buffer at 4 °C. The peptide mixtures were then incubated 
with P-Tyr-1000 beads for 30 min with gentle rotation. To 
remove non-specifically bound peptides, the beads were 
washed thrice with ice cold IAP buffer and twice with ice 
cold water. Elution of enriched peptides from beads was 
carried out at room temperature using 0.15% TFA. This 
step was repeated twice and followed by cleanup of the 
samples using  C18 Stage tips.
LC–MS/MS analysis of enriched peptides
The enriched phosphotyrosine-containing peptides were 
analyzed on an Orbitrap Fusion Lumos Tribrid mass 
spectrometer (Thermo Electron, Bremen, Germany) 
interfaced with EASY-nLC II nanoflow liquid chromatog-
raphy system equipped with an EASY-Spray ion source. 
(Thermo Scientific, Odense, Denmark). Peptide digests 
were reconstituted in 0.1% formic acid and loaded onto 
trap column (Thermo Scientific™ Acclaim™ PepMap™ 
100 C18 LC) at a flow rate of 3  µl/min. Peptides were 
separated on an analytical column (EASY-Spray™ LC) at 
a flow rate of 300 nl/min using a step gradient of 5–18% 
solvent B (0.1% formic acid in 95% acetonitrile) for first 
110  min and 18–30% solvent B for 110–160  min. The 
total run time was set to 180  min. The mass spectrom-
eter was operated in a data-dependent acquisition mode. 
A survey full scan MS (from m/z 350–1500) was acquired 
in the Orbitrap with a resolution of 120,000 at 400 m/z. 
The AGC target for MS1 was set as 1 × 106 and ion filling 
time set 60 ms. The most intense ions with charge state 
≥ 2 were isolated in 3 s cycle and fragmented using HCD 
fragmentation with 32% normalized collision energy and 
detected at a mass resolution of 30,000 at 200 m/z. The 
AGC target for MS/MS was set as 5 × 104 and ion filling 
time set 200 ms dynamic exclusion was set for 30 s with a 
10 ppm mass window.
For the PRM analysis, the enriched phosphotyrosine 
containing peptides were analyzed on an Orbitrap Fusion 
Tribrid mass spectrometer interfaced with EASY-nLC II 
nanoflow liquid chromatography system. Peptide digests 
were reconstituted in 0.1% formic acid and loaded onto 
a trap column at a flow rate of 3 µl/min and resolved on 
analytical column. The mass spectrometer was operated 
in data-independent acquisition PRM mode. A survey 
full scan MS (from m/z 350–1700) was acquired in the 
Orbitrap at a resolution of 120,000 at 400 m/z. A targeted 
list of precursor ions with charge state ≥ 2 were isolated 
and fragmented using HCD fragmentation with 32% nor-
malized collision and detected at a mass resolution of 
30,000 at 400 m/z. The data were subsequently analyzed 
using Skyline [28].
Data analysis
The MS/MS database searches were carried out using 
SEQUEST search algorithms against RefSeq human pro-
tein database using Proteome Discoverer 2.1 (Thermo 
Fisher Scientific, Bremen, Germany). The workflow 
included spectrum selector, SEQUEST search nodes, 
peptide validator and phosphoRS nodes. Oxidation of 
methionine, phosphorylation at serine, threonine and 
tyrosine (+ 79.966 Da) were set as variable modifications 
and carbamidomethylation of cysteine was set as a fixed 
modification. MS and MS/MS mass tolerances were set 
to 10 ppm and 0.05 Da, respectively. Trypsin was speci-
fied as protease and a maximum of one missed cleavage 
was allowed. Target-decoy database searches used for 
calculation of false discovery rate (FDR) and for peptide 
identification FDR was set at 1%. The probability of the 
phosphorylation site was calculated using phosphoRS 3.1 
node in the Proteome Discoverer. Phosphopeptides with 
> 75% localization probability was considered for further 
analysis.
Availability of data
The mass spectrometry derived data have been depos-
ited to the ProteomeXchange Consortium (http://prote 
omece ntral .prote omexc hange .org) via the PRIDE partner 
repository with the dataset identifierPXD009152.
Bioinformatics analysis
Molecular function and localization of phosphoproteins 
was obtained from the Human Protein Reference Data-
base (HPRD) [29]. The involvement of theses phospho-
proteins in biological processes was also obtained from 
HPRD.
Results
LC–MS/MS analysis of tyrosine phosphorylated peptides 
in CSF
The CSF proteins were digested with trypsin, phos-
photyrosine peptides were enriched, and LC–MS/
MS analysis was conducted as described in Methods 
[25, 30, 31] (Fig.  1). We identified 111 phosphotyros-
ine peptides mapping to 66 proteins (Additional file  1: 
Table  S1) of which 38 were identified from at least two 
samples (Fig. 2a). These identified phosphotyrosine pep-
tides are corresponding to 66 proteins (Additional file 2: 
Table S2). We have used tyrosine phosphorylated peptide 
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immunoaffinity enrichment-based technique along 
with high-resolution mass spectrometry on an Orbitrap 
Fusion Lumos Tribrid mass spectrometer—the latest 
generation mass spectrometer for deep characterization 
of phosphotyrosine peptides in CSF.  
Classification of tyrosine phosphorylated CSF proteins 
using gene ontology
To obtain deeper biological insights into the identified 
CSF tyrosine phosphorylated proteins, we categorized 
them based on their subcellular localization, molecular 
function and biological process (Fig. 2b–d). The secretory 
proteins were mostly hormones, cytokines and proteases 
that possess important regulatory functions and are 
released for cell to cell interaction and communication. 
Of the 66 proteins identified, 33 proteins have signal pep-
tides and 13 have transmembrane domains. This analy-
sis reveals that the majority of tyrosine phosphorylated 
proteins in CSF are destined towards the secretory path-
way. Our analysis showed that a majority of the tyrosine 
phosphorylated proteins were localized to the plasma 
membrane (34%), followed by extracellular matrix (26%), 
cytosol (26%) and endoplasmic reticulum (4%) (Fig. 2b). 
Most of the proteins were found to be involved in cell 
adhesion activity, transport activity or kinase activity 
(Fig.  2c). A majority of the proteins identified were cell 
adhesion proteins, which included CHL1, SPP1 and 
NRXN3. The CHL1 cell adhesion molecule L1 like is 
a neural cell adhesion molecules and it is significantly 
associated with schizophrenia [32, 33]. SPP1 (secreted 
phosphoprotein 1) and NRXN3 (neurexin 3) are already 
known to be associated with Alzheimer’s disease [34, 
35]. The other major categories of proteins identified 
were kinases (15%), cytoskeletal proteins (14%), mem-
brane and cell junction proteins (13%) and the transport/
carrier proteins. The identified CSF proteins were also 
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Fig. 1 A schematic of the workflow used to study the phosphotyrosine profiling of CSF. Phosphotyrosine peptides from CSF of three NPH patients 
were enriched using antibody-based approach and enriched peptides were analyzed on mass spectrometer. The subset of phosphotyrosine sites 
identified in our discovery experiment were validated in the another set of 8 normal individual CSF using parallel reaction monitoring (PRM) assays
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categorized based on their biological processes. Most of 
these proteins were found to be involved in cell commu-
nication and signal transduction, followed by transport, 
cell growth and energy pathways as shown in Fig. 2d.
Targeted analysis of a subset of tyrosine phosphorylated 
peptides in CSF
The results from the discovery experiments were 
subsequently validated in CSF of cognitively nor-
mal individuals (N = 8) using a targeted parallel reac-
tion monitoring (PRM) approach. We selected a set 
of tyrosine phosphorylated peptides based on their 
abundance and biological role for analysis in PRM 
mode. The tyrosine phosphorylated peptides iden-
tified in normal individual CSF using PRM mode 
includes proteins DBI (diazepam binding inhibi-
tor), acyl-CoA binding protein, B4GAT1 (beta-1, 
3-N-acetylglucosaminyltransferase), CD59, transferrin 
and Thy-1 cell surface antigen. The list of the tyrosine 
phosphorylated peptides and its corresponding pro-
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Fig. 2 Summary of phosphotyrosine-containing peptides/proteins in CSF. a Overlap of phosphotyrosine peptides identified from three individuals. 
We identified 18 phosphopeptides common across the CSF of three individuals, b localization of tyrosine phosphorylated proteins identified in CSF 
of NPH patients. c Functional categorization of tyrosine phosphorylated protein identified in CSF based on the molecular function, d functional 
categorization of tyrosine phosphorylated protein identified in CSF based on the biological processes
Table 1 A list of proteins that are validated using PRM
Gene symbol Protein Peptide sequence Site
DBI Diazepam binding inhibitor, 
acyl-CoA binding protein
TKPSDEEMLFIYGHYK Y90




CD59 CD59 glycoprotein prepro-
protein
ENELTYYCCK Y86
THY-1 Thy-1 cell surface antigen VLYLSAFTSK Y90
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the each of the phosphopeptides in the different sam-
ples is shown in Additional file 3: Figure S1. 
Discussion
Phosphotyrosine profiling of cerebrospinal fluid
Since the alterations in tyrosine phosphorylation of 
proteins in the brain can be reflected in the CSF, such 
proteins can be excellent candidates as biomarkers for 
neurodegenerative diseases such as AD and PD. In 
spite of this, there are no reports that describe phos-
photyrosine profiling of proteins in CSF. Proteins can 
be phosphorylated on serine, threonine and tyrosine. 
Of these, the phosphorylation on tyrosine residues is 
much less abundant than either serine or threonine 
residues. Owing to this, the identification of phos-
photyrosine modifications is mostly conducted after 
enriching phosphotyrosine-containing peptides using 
anti-phosphotyrosine antibodies from large amounts 
of proteins (> 20  mg). Because the protein concentra-
tion of CSF is only ~ 0.15 to 0.6 mg/ml, large volumes 
of CSF are required for such an analysis. To over-
come this limitation, we used three sets of CSF sam-
ples (100  ml each generating ~ 50  mg protein in each 
instance) obtained from subjects with NPH and pro-
cessed them independently. In this study, we employed 
antibody-based enrichment with Orbitrap Fusion 
Lumos Tribrid mass spectrometer—the latest genera-
tion mass spectrometer for identification of tyrosine 
phosphorylation in the cerebrospinal fluid. We identi-
fied 111 phosphotyrosine peptides corresponds to 66 
proteins.
Proteins uniquely identified in this study
To identify proteins which have not been previously 
reported in the CSF, we compared our data with proteins 
cataloged in the CSF-PR database. CSF-PR is an online 
repository of mass spectrometry-based proteomics 
experiments on human cerebrospinal fluid [36]. We iden-
tified 24 proteins that have not been previously detected 
in cerebrospinal fluid. A partial list of uniquely iden-
tified proteins in this study is provided in Table  2. This 
list includes proteins CWF19 like 1, cell cycle control 
(CWF19L1), inositol polyphosphate-5-phosphatase D 
(INPP5D), beta-1, 4-glucuronyltransferase 1 (B4GAT1), 
protein kinase C delta (PRKCD), NCK adaptor protein 2 
(NCK2), glucose-6-phosphate dehydrogenase (G6PD).
Mutations in the CWF19 gene, which encodes CWF19 
protein family have been associated with ataxia and mild 
mental retardation [37]. CWF19 has a strong association 
with late-onset Alzheimer’s disease [38]. Our study iden-
tified phosphorylation of CWF19 at Y192 and T186 as it 
was located on the same phosphopeptide. Phosphoryla-
tion of these sites has not been reported previously. The 
representative MS/MS for the doubly phosphorylated 
peptide is shown in Fig.  3a. Glucose-6-phosphate dehy-
drogenase is a cytosolic enzyme and its main function is 
to produce NADPH, an important electron donor. Activ-
ity of G6PD is increased in the inferior temporal cortex of 
Alzheimer individuals [39]. G6PD plays an important role 
in compensating oxidative stress produced in Alzheimer’s 
disease [40]. In another study, G6PD enzyme activity in 
serum of AD and control subjects was measured. G6PD 
activity is two times higher in AD patients as compared 
to controls [41]. We identified G6PD phosphorylation at 
Table 2 A list of proteins identified that are unique in this study
Gene symbol Protein Peptide sequence Site
CWF19L1 CWF19 like 1, cell cycle control CGSALVSSLATGLKPRYHFAALEK Y192
INPP5D Inositol polyphosphate-5-phosphatase D EKLYDFVK Y865
B4GAT1 Beta-1, 4-glucuronyltransferase 1 YEAAVPDPR Y163
PTPN11 Tyrosine-protein phosphatase non-receptor type 11 IQNTGDYYDLYGGEK Y584
G6PD Glucose-6-phosphate dehydrogenase VQPNEAVYTK Y432
FGR FGR proto-oncogene LIKDDEYNPCQGSK Y412
PXN Paxillin VGEEEHVYSFPNK Y124
CALM 2 Calmodulin 2 DGNGYISAAELR Y148
Fig. 3 MS/MS spectra for the phosphotyrosine-containing peptides/proteins uniquely identified in ours study. a MS/MS spectra for doubly 
phosphorylated peptide identified from CWF19, b representative MS/MS spectra for phosphorylated peptide identified from G6PD, c representative 
MS/MS spectra for phosphorylated peptide identified from PTPN6 and d representative MS/MS spectra for phosphorylated peptide identified from 
PXN
(See figure on next page.)
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Y401 in CSF. The representative MS/MS spectra is shown 
in the Fig. 3b.
PTPN6 belongs to a member of the protein tyrosine 
phosphatase (PTP) family. It involved in the cell differ-
entiation, cell growth, differentiation, mitotic cycle, and 
oncogenic transformation [42]. PTPN6 expression was 
increased in glioma and its expression correlating with 
poor survival. Its expression controlled epigenetically 
and impacts the response to chemotherapy [43]. In our 
analysis, we detected phosphorylation at Y 584. The MS/
MS spectrum for this peptide is shown in Fig. 3c. Paxil-
lin (PXN) is involved in actin-membrane attachment at 
sites of cell adhesion to the extracellular matrix. It is an 
adapter protein which plays an important scaffolding role 
at focal adhesions by employing structural and signal-
ing molecules involved in cell movement and migration, 
when phosphorylated on specific Tyr and Ser residues 
[44]. We have detected phosphorylated paxillin in CSF. 
The MS/MS of the phosphopeptide is shown in the 
Fig. 3d. These newly identified CSF proteins will help to 
increase knowledge of extracellular signaling and under-
standing pathology of neurological disorders.
Targeted analysis of tyrosine phosphorylated CSF proteins
The results from the discovery experiments were subse-
quently validated in CSF of cognitively normal individu-
als using a targeted parallel reaction monitoring (PRM) 
approach. This tyrosine phosphorylated peptides corre-
sponds to the proteins DBI (diazepam binding inhibitor), 
acyl-CoA binding protein, B4GAT1 (beta-1, 3-N-acetyl-
glucosaminyltransferase), CD59, transferrin and Thy-1 
cell surface antigen. Validation of these tyrosine phos-
phorylated peptides in 8 CSF samples from cognitively 
normal healthy controls is a preliminary finding that 
needs to be replicated in a larger cohort. Unlike other 
biofluids, CSF is difficult to obtain, especially CSF from 
cognitively normal healthy controls. Although the sam-
ple size for the validation is small, these findings are quite 
promising.
DBI (diazepam binding inhibitor) is a polypeptide that 
was initially identified from rat brains [45]. This protein 
is involved in lipid metabolism and the displacement of 
beta-carbolines and benzodiazepines, which regulate 
signal transduction at type-a gamma-aminobutyric acid 
receptor located in brain synapses. Multiple missense 
mutations have been reported in the DBI gene in schizo-
phrenia [46]. It regulates steroidogenesis in mitochondria 
and also glucose-stimulated insulin secretion [47]. DBI 
gene polymorphisms are also associated with anxiety 
disorders [48]. As DBI can be a potential candidate gene 
for psychiatric phenotypes including anxiety, mood, and 
psychotic disorders, its concentration has been investi-
gated in the plasma of epileptic patients and found to be 
elevated [49]. The transitions for the peptide correspond-
ing to phosphorylated DBI are shown in Fig. 4a.
Transferrin plays important roles in iron transport 
from the intestine, reticuloendothelial system, and liver 
parenchymal cells to all cells in the body for prolifera-
tion. It also plays important roles in the removal of aller-
gens from the serum. Several mass-spectrometry based 
method were established for the detection of glycoforms 
for diagnosis of congenital disorders [50]. Mutations in 
transferrin lead to an increased risk of Alzheimer’s dis-
ease [51]. The N-glycan proteoform of CSF transferrin is 
a potential biomarker for normal pressure hydrocephalus 
(iNPH) [52]. Transferrin has recently been shown to be 
a potent in vitro inhibitor of self-association of Aβ [53]. 
The transitions for the peptide corresponding to phos-
phorylated transferrin are shown in Fig. 4b.
CD 59 is a surface glycoprotein that controls comple-
ment-mediated cell lysis, which has been identified previ-
ously in plasma, urine, saliva and  CSF [54]. It has been 
reported that the concentration of CD 59 is elevated in 
multiple sclerosis patients [55]. We have identified phos-
phorylation of CD 59 at Y87. The transitions for the pep-
tide corresponding to phosphorylated CD 59 are shown 
in Fig.  4c. Thy-1 antigen is a cell surface glycoprotein, 
which is the most abundant glycoprotein on mammalian 
neurons [56, 57]. It has also been reported as a cancer 
stem cell marker in high grade gliomas [58]. In the nerv-
ous system, Thy-1 plays an important role in cell commu-
nication [59]. We have detected tyrosine phosphorylated 
sites on Thy-1 in CSF samples using the PRM approach. 
B4GAT1 is a member of the beta-1,3-N-acetylglucosa-
minyltransferase family and it is a transmembrane pro-
tein having enzymatic activity. A truncating mutation 
in B4GAT1 is known to causes severe Walker-Warburg 
syndrome, a congenital muscular dystrophy [60]. Dys-
troglycan organizes basement of cell membrane by inter-
acting ligands in the extracellular matrix. BGAT1 play 
important role in activation of dystroglycan [61]. The 
transitions for the peptide corresponding to phospho-
rylated Beta-1,4-glucuronyltransferase 1 are shown in 
Fig.  4d. The PRM analysis of normal CSF samples con-
firms that these tyrosine phosphorylated peptides are 
easily detected in individual normal CSF samples using 
the PRM approach.
Conclusions
In this study, we have investigated tyrosine phosphoryla-
tion in cerebrospinal fluid and identified several novel 
phosphosites. The study represents the first deep phos-
photyrosine proteome profiling of cerebrospinal fluid. 
Further work is necessary in larger cohorts compar-
ing cognitively normal and diseased subjects to deter-
mine if any of these phosphoproteins play a role in 
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pathophysiology or can serve as biomarkers in neurologi-
cal disorders.
Additional files
Additional file 1: Table S1. A summary of tyrosine phosphopeptides 
identified in CSF.
Additional file 2: Table S2. A summary of tyrosine phosphorylated 
proteins identified in CSF.
Additional file 3: Figure S1. A relative abundance of the tyrosine phos-
phorylated peptides in the CSF samples.
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